| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/12/2004 | WO2004013280A2 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING |
| 02/12/2004 | WO2004013179A1 Conjugate of notch signalling pathway modulators and their use in medical treatment |
| 02/12/2004 | WO2004013174A1 Use of disease-associated gene |
| 02/12/2004 | WO2004013165A1 Pegylated t1249 polypeptide |
| 02/12/2004 | WO2004013164A1 Pegylated t20 polypeptide |
| 02/12/2004 | WO2004013160A2 Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
| 02/12/2004 | WO2004013157A2 REDUCING NgR-p75 MEDIATED BY INHIBITION OF AXON REGENERATION |
| 02/12/2004 | WO2004013098A1 Novel gamma-lactams as beta-secretase inhibitors |
| 02/12/2004 | WO2004012816A1 Antibacterial ester macrocycles |
| 02/12/2004 | WO2004012775A2 Bicistronic vector encoding a vegf and an fgf, use thereof |
| 02/12/2004 | WO2004012772A1 Oral administration of calcitonin |
| 02/12/2004 | WO2004012771A1 Pharmaceutical compositions comprising cyclosporin for oral administration |
| 02/12/2004 | WO2004012770A1 Oral pharmaceutical compositions comprising cyclosporin |
| 02/12/2004 | WO2004012769A1 Therapeutic inhibitionof protein kinases in cancer cells |
| 02/12/2004 | WO2004012768A1 Tolerance induction with help of a combination of a lfa-1 inhibitor and a costimulation inhibitor and/or a mtor inhibitor |
| 02/12/2004 | WO2004012762A2 Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
| 02/12/2004 | WO2004012761A1 Methods of use of compounds with preptin function |
| 02/12/2004 | WO2004012760A1 Preptin methods of use |
| 02/12/2004 | WO2004012759A2 Use of erythropoietin |
| 02/12/2004 | WO2004012758A1 Use of tgf beta ig-h3 for preventing and treating obesity, diabetes and/or metabolic syndrome |
| 02/12/2004 | WO2004012757A2 Apolipoprotein l-i for the treatment or diagnosis of prypanosomaldiseases |
| 02/12/2004 | WO2004012756A1 New cytotoxic cyclopeptide and its use for the treatment of cancer |
| 02/12/2004 | WO2004012732A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 02/12/2004 | WO2004012716A1 Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant |
| 02/12/2004 | WO2004012712A1 Methods and compositions for treating benign gynecological disorders, contraception, and hormone replacement |
| 02/12/2004 | WO2004012709A1 Cochleates without metal cations as the bridging agents |
| 02/12/2004 | WO2004012690A1 A multi component moisture triggered contolled release system that imparts long lasting cooling sensation on the target site and/or provides high impact fragrance or flavor burst |
| 02/12/2004 | WO2004012681A2 Cancer vaccines containing epitopes of oncofetal antigen |
| 02/12/2004 | WO2004012673A2 Methods and reagents relating to inflammation and apoptosis |
| 02/12/2004 | WO2004012669A2 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 02/12/2004 | WO2004012662A2 Improved treatment of cancer with glutamine |
| 02/12/2004 | WO2004012574A2 Negative selections assays, and compositions thereof |
| 02/12/2004 | WO2004012522A1 Compositions comprising lactoferrin |
| 02/12/2004 | WO2003097106A3 Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent |
| 02/12/2004 | WO2003096979A3 Drug therapy for celiac sprue |
| 02/12/2004 | WO2003094957A3 Methods of therapy for inducing tolerance |
| 02/12/2004 | WO2003092474A3 Vascularization enhanced graft constructs |
| 02/12/2004 | WO2003091414A3 Adipocyte complement related protein zacrp8 |
| 02/12/2004 | WO2003091384A3 A role for survivin in apoptosis of myeloid cells |
| 02/12/2004 | WO2003089584A3 Use of parapox b2l protein to modify immune responses to administered antigens |
| 02/12/2004 | WO2003089456A3 Peptide inhibitors of protein kinase c |
| 02/12/2004 | WO2003087832A3 Diagnosis of carcinoma using raigi polypeptides |
| 02/12/2004 | WO2003079997A3 Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma |
| 02/12/2004 | WO2003079885A3 Inhalable sustained therapeutic formulations |
| 02/12/2004 | WO2003077882A3 Preparation of sterile stabilized nanodispersions |
| 02/12/2004 | WO2003076583A3 Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria |
| 02/12/2004 | WO2003070968A3 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE (GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 02/12/2004 | WO2003070769A3 Organic compounds having anti-angiogenic activity |
| 02/12/2004 | WO2003064463B1 Pluripotency determining factors and uses thereof |
| 02/12/2004 | WO2003064453A3 Trojan inhibitors, method for the production and use thereof |
| 02/12/2004 | WO2003062467A3 Tissue rejection |
| 02/12/2004 | WO2003062261A3 Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use |
| 02/12/2004 | WO2003057158A3 Method of treating apoptosis and compositions thereof |
| 02/12/2004 | WO2003053325A8 Microencapsulation of drugs by solvent exchange |
| 02/12/2004 | WO2003050502A3 Prospective identification and characterization of breast cancer stem cells |
| 02/12/2004 | WO2003050301A3 Susceptibility locus for schizophrenia |
| 02/12/2004 | WO2003050141B1 Calpain activators |
| 02/12/2004 | WO2003044167A3 Antisense modulation of human fxr expression |
| 02/12/2004 | WO2003044041A3 Alpha-fetoprotein peptides and uses for imaging |
| 02/12/2004 | WO2003039346A3 Diagnostics and therapeutics for ocular abnormalities |
| 02/12/2004 | WO2003039331A3 Method for improving stability of a bone-connecting implant |
| 02/12/2004 | WO2003037916A3 Linear basic compounds having nk-2 antagonist activity and formulations thereof |
| 02/12/2004 | WO2003035012A3 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof |
| 02/12/2004 | WO2003034996B1 Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment |
| 02/12/2004 | WO2003033653B1 Affinity enhancement agents |
| 02/12/2004 | WO2003033526A3 Synthesis of cyclosporin analogs |
| 02/12/2004 | WO2003031650A3 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease |
| 02/12/2004 | WO2003031589A8 Peptides and related compounds having thrombopoietic activity |
| 02/12/2004 | WO2003025010A3 Human delta-n p73 molecules and uses thereof |
| 02/12/2004 | WO2003022225A3 Compositions comprising mixtures of therapeutic proteins and methods of producing the same |
| 02/12/2004 | WO2003022213A3 Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| 02/12/2004 | WO2003020906A3 Multivalent protein conjugate with multiple ligand-binding domains of receptors |
| 02/12/2004 | WO2003015710A3 Combined drug and csf removal therapies and systems |
| 02/12/2004 | WO2003014329A3 Modulation of angiogenesis by a-beta peptides |
| 02/12/2004 | WO2003011213A3 Method for treating diabetes and obesity |
| 02/12/2004 | WO2003008438A3 Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
| 02/12/2004 | WO2002100344A3 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 02/12/2004 | WO2002100330A3 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 02/12/2004 | WO2002095051A3 Mage-a3 peptides presented by hla class ii molecules |
| 02/12/2004 | WO2002095010A3 Human secreted proteins |
| 02/12/2004 | WO2002090542A8 Antigenic epitopes of factor viii, inhibitors directed against said epitopes and use thereof |
| 02/12/2004 | WO2002081507A3 Interferon gamma polypeptide variants |
| 02/12/2004 | WO2002080848A3 Methods and materials for cancer treatment |
| 02/12/2004 | WO2002077232A3 Compositions and methods relating to breast specific genes and proteins |
| 02/12/2004 | WO2002076507A3 Uses of opg ligand to modulate immune responses |
| 02/12/2004 | WO2002072771A3 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use |
| 02/12/2004 | WO2002071927A3 Diagnosis and treatment of skeletal degeneration conditions |
| 02/12/2004 | WO2002069907A8 Anti-neovasculature preparations for cancer |
| 02/12/2004 | WO2002068649A3 Proteins and nucleic acids encoding same |
| 02/12/2004 | WO2002068461A3 Heterocarpine, a human ghrh-binding protein |
| 02/12/2004 | WO2002066647A3 Type 2 ctokine receptor and nucleic acids encoding same |
| 02/12/2004 | WO2002066063A8 Remedies for metabolic bone diseases |
| 02/12/2004 | WO2002064779A8 Peptide inhibitors of cellular proliferation |
| 02/12/2004 | WO2002062952A3 Non-cytotoxic pap mutants |
| 02/12/2004 | WO2002057454A3 Receptors and membrane-associated proteins |
| 02/12/2004 | WO2002055702A3 Human proteins, polynucleotides encoding them and methods of using the same |
| 02/12/2004 | WO2002053700A3 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 02/12/2004 | WO2002053580A3 Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| 02/12/2004 | WO2002045493A3 Transgenic mice containing phosphatase target gene disruptions |
| 02/12/2004 | WO2002035981A3 Methods and compositions for the treatment of human immunodeficiency virus infection |